VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Leukemia, Myeloid, AcuteAML Stage, Adult
Interventions
DRUG

Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen

"venetoclax combining chidamide and azacitidine (VCA) 28 days per cycle × 2 cycles; 1) chidamide 30mg biw × 2weeks;2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7 dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen 28 days per cycle ×2 cycles;~1)dicitabine 25mg d1-3,2)liposome mitoxantrone 20mg d4,3)cytarabine 10mg/m2 Q12h d1-7 4)G-CSF 300ug d-1 until WBC \> 20×109/L"

Trial Locations (1)

361003

RECRUITING

Bing Xu, Xiamen

All Listed Sponsors
collaborator

Chipscreen Biosciences, Ltd.

INDUSTRY

collaborator

CSPC Pharmaceutical Group Limited

INDUSTRY

collaborator

Fujian Provincial Hospital

OTHER

collaborator

Fujian Cancer Hospital

OTHER_GOV

collaborator

Zhangzhou manicipal hospital of Fujian Province

UNKNOWN

collaborator

Jieyang People's Hospital

OTHER

collaborator

Huizhou Municipal Central Hospital

OTHER

lead

The First Affiliated Hospital of Xiamen University

OTHER